Clinical Trial Results:
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy with Rucaparib
Summary
|
|
EudraCT number |
2020-001538-37 |
Trial protocol |
CZ HU PL ES IT |
Global end of trial date |
08 Mar 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jun 2024
|
First version publication date |
09 Jun 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CO-338-111
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04676334 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
pharmaand GmbH
|
||
Sponsor organisation address |
Taborstraße 1, Wien, Austria, 1020
|
||
Public contact |
Medical Information Department pharmaand GmbH, pharmaand GmbH, +43 13560006, medinfo@pharmaand.com
|
||
Scientific contact |
Medical Information Department pharmaand GmbH, pharmaand GmbH, +43 13560006, medinfo@pharmaand.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
08 Mar 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
08 Mar 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study (2013-000517-20; 2013-000518-39; 2016-000816-14; 2016-003162-13) with continued access to treatment for as long as they continue to benefit. Participants in long-term follow-up (LTFU) in a parent study (2016-000816-14) may also enroll in this study for continued data collection, as applicable based on parent study objectives.
|
||
Protection of trial subjects |
The study was performed in compliance with the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and regulatory requirements as applicable.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Apr 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Brazil: 10
|
||
Country: Number of subjects enrolled |
Czechia: 2
|
||
Country: Number of subjects enrolled |
Hungary: 2
|
||
Country: Number of subjects enrolled |
Spain: 1
|
||
Country: Number of subjects enrolled |
Canada: 7
|
||
Country: Number of subjects enrolled |
Israel: 2
|
||
Country: Number of subjects enrolled |
Russian Federation: 8
|
||
Country: Number of subjects enrolled |
Italy: 2
|
||
Worldwide total number of subjects |
34
|
||
EEA total number of subjects |
7
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
28
|
||
From 65 to 84 years |
6
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Only serious adverse event (SAE) and adverse event of special interest (AESI) safety data were collected, Other (non-serious) adverse events (AEs) were not collected. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Safety data were collected only for the Rucaparib arm (participants who received rucaparib during this study); safety data were not collected for the Long-term Follow-up arm (participants who did not receive rucaparib during this study). | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||
Arm title
|
Rucaparib | ||||||||||||
Arm description |
Participants received rucaparib at a dose and schedule last taken in the parent study, or per investigator decision. | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Rucaparib
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
CO-338, Rubraca
|
||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Rucaparib was administered daily.
|
||||||||||||
Arm title
|
Long-term Follow-up | ||||||||||||
Arm description |
Participants discontinued rucaparib treatment and were in long-term follow-up in the parent study. | ||||||||||||
Arm type |
No intervention | ||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||
|
|||||||||||||
Notes [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left. Justification: No study drug was administered to the Long-term Follow-up arm. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Rucaparib
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received rucaparib at a dose and schedule last taken in the parent study, or per investigator decision. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Long-term Follow-up
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants discontinued rucaparib treatment and were in long-term follow-up in the parent study. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Rucaparib
|
||
Reporting group description |
Participants received rucaparib at a dose and schedule last taken in the parent study, or per investigator decision. | ||
Reporting group title |
Long-term Follow-up
|
||
Reporting group description |
Participants discontinued rucaparib treatment and were in long-term follow-up in the parent study. | ||
Subject analysis set title |
Enrolled Population
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Enrolled Population: all participants who were enrolled in the study.
|
||
Subject analysis set title |
Safety Population
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Safety Population: all participants who received rucaparib during the study (Rucaparib arm), safety data were not collected for the Long-term Follow-up arm.
|
|
|||||||||||
End point title |
Number of Participants Experiencing SAEs and AESIs [1] [2] | ||||||||||
End point description |
An SAE was any untoward medical occurrence that occurred at any dose, or after informed consent was given and prior to dosing if the SAE was related to a study procedure, that: resulted in death; was life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly or birth defect; or was an important medical event that may not have resulted in death, was not life-threatening, or did not require hospitalization but may be considered an SAE, based on appropriate medical judgment. An AESI was defined as any AE of scientific and medical concern specific to the sponsor’s product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate. A summary of all SAEs regardless of causality is located in the ‘Adverse events’ Section.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
From first dose of rucaparib through 28 days after receiving last dose of rucaparib (approximately 20 months)
|
||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only the number of participants was collected for this end point. [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Safety data were collected only for the Rucaparib arm (participants who received rucaparib during this study); safety data were not collected for the Long-term Follow-up arm (participants who did not receive rucaparib during this study). |
|||||||||||
|
|||||||||||
Notes [3] - Safety Population |
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From first dose of rucaparib through 28 days after receiving last dose of rucaparib (approximately 20 months)
|
||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Only SAE and AESI safety data were collected, Other (non-serious) AEs were not collected. Safety data were collected only for the Rucaparib arm; safety data were not collected for the Long-term Follow-up arm. Data reported for Safety Population: all participants who received rucaparib during the study.
|
||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.1
|
||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Rucaparib
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received rucaparib at a dose and schedule last taken in the parent study, or per investigator decision. | ||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Only SAE and AESI safety data were collected, Other (non-serious) AEs were not collected. Safety data were collected only for the Rucaparib arm (participants who received rucaparib during this study); safety data were not collected for the Long-term Follow-up arm (participants who did not receive rucaparib during this study). |
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Only SAE and AESI safety data were collected, Other (non-serious) AEs were not collected. Safety data were collected only for the Rucaparib arm; safety data were not collected for the Long-term Follow-up arm. |